Volanesorsen: Ph III COMPASS data

The 26-week, double-blind, international Phase III COMPASS trial in 113 patients with severe hypertriglyceridemia showed that once-weekly 300 mg subcutaneous volanesorsen met the primary endpoint of reducing mean triglyceride levels from baseline to 13 weeks vs. placebo (71.2% vs. 0.9%, p<0.0001). Ionis said the treatment effect was sustained through the end of the 26-week treatment period. Additionally, a significantly greater proportion of patients treated with volanesorsen achieved triglyceride levels of <500 mg/dL after 13 weeks vs. placebo (82% vs. 14%, p<0.0001). In a subset of 7 patients with familial chylomicronemia syndrome, volanesorsen reduced mean triglyceride levels from baseline to 13 weeks by 73% vs. an increase of 70% for placebo...